TrialBMC cancer2023

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Lyn Ley Lam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.